Tesofensine and metoprolol for treatment of hypertension

Abstract

The present invention relates to treatment of hypertension using a combination of tesofensine and metoprolol. The treatment is particularly well suited for the treatment of hypertensive obese subjects and hypertensive diabetic subjects.

What is claimed is: 
     
         1 . A method for treating hyperphagia in a subject having Prader Willi Syndrome comprising orally administering to the subject 0.1 mg to 1 mg of tesofensine or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method according to  claim 1 , wherein the tesofensine or a pharmaceutically acceptable salt thereof is tesofensine citrate. 
     
     
         3 . The method according to  claim 1 , wherein the tesofensine or a pharmaceutically acceptable salt thereof is tesofensine tartrate. 
     
     
         4 . The method according to  claim 1 , wherein the tesofensine or a pharmaceutically acceptable is administered in a tablet. 
     
     
         5 . The method according to  claim 1 , wherein the tesofensine or a pharmaceutically acceptable is administered in a capsule. 
     
     
         6 . The method according to  claim 1 , wherein the tesofensine or a pharmaceutically acceptable salt thereof is administered to said subject at a dose of 0.25 mg to 0.75 mg of tesofensine per day. 
     
     
         7 . The method according to  claim 1 , wherein the tesofensine, or a pharmaceutically acceptable salt thereof, is administered at about 0.25 mg per day. 
     
     
         8 . The method according to  claim 1 , wherein the tesofensine, or a pharmaceutically acceptable salt thereof, is administered at about 0.5 mg per day. 
     
     
         9 . The method according to  claim 1 , wherein the subject is an adult human. 
     
     
         10 . The method according to  claim 1 , wherein the subject has a body mass index (BMI) of 25 kg/m 2  or a BMI of above 25 kg/m 2 , prior to the administration. 
     
     
         11 . The method according to  claim 1 , wherein the administration results in reduction of the subject's BMI, as compared to prior to the administration. 
     
     
         12 . The method according to  claim 1 , wherein the subject is below 18 years of age. 
     
     
         13 . The method according to  claim 1 , wherein the administration results in decrease of the subject's waist circumference, as compared to prior to the administration.